The DAPA-CKD study extended these evidences to the more general population of CKD, with or without T2D with an eGFR of 25 to 75 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio of 200 to 5000 mg/g providing clinical evidence of the beneficial role of SGLT2is on the decline in the eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes, irrespective of the presence of T2D [40]. This evidence concerns the gene ALB and chronic kidney disease.